Rajarshi Banerjee

1 month ago | hcplive.com | Rajarshi Banerjee

New research is shedding light on the value of iron corrected T1 (cT1) as a reproducible biomarker capable of predicting both cardiovascular and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).1The study, coined by investigators as the largest prospective analysis of cardiac and liver imaging and cardiac and liver events to date, leveraged MRI data for > 28,000 UK Biobank participants.

2 months ago | kevinmd.com | Dawn Baker |L. Joseph Parker |Rajarshi Banerjee |Michele Luckenbaugh

Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes!Psychiatrist Muhamad Aly Rifai discusses his article, “The future of psychiatry: How AI and genetics are reshaping mental health care.” Muhamad explores how the integration of genetic research, biomarkers, electrophysiology, and artificial intelligence is transforming psychiatry into a more precise and preventative field.

Mar 19, 2025 | consultantlive.com | Rajarshi Banerjee

New research suggests multiparametric magnetic resonance imaging (mpMRI) with LiverMultiScan is a viable tool for identifying and managing patients with metabolic dysfunction-associated steatotic liver disease (MASLD), offering a cost-effective alternative to liver biopsy and other noninvasive tests.1 “Multiparametric MRI is a very great technology for tissue characterization, and since the diagnosis of MASH, metabolic associated steatohepatitis, is a tissue characterization diagnosis… the...

Mar 19, 2025 | hcplive.com | Rajarshi Banerjee

New research suggests multiparametric magnetic resonance imaging (mpMRI) with LiverMultiScan is a viable tool for identifying and managing patients with metabolic dysfunction-associated steatotic liver disease (MASLD), offering a cost-effective alternative to liver biopsy and other noninvasive tests.1 “Multiparametric MRI is a very great technology for tissue characterization, and since the diagnosis of MASH, metabolic associated steatohepatitis, is a tissue characterization diagnosis… the...

Mar 4, 2025 | medium.com | Rajarshi Banerjee

Rajarshi Banerjee·Follow4 min read·--The way we connect in business is evolving rapidly. With digital transformation accelerated by recent disruptions, the B2B event landscape is set for a remarkable shift over the next few years. In 2025–2026, hybrid models, immersive technologies, data-driven personalization, and sustainability will not only redefine event formats but also reshape business outcomes.